The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers - Full Text View

Sponsor:	Tel-Aviv Sourasky Medical Center
Information provided by:	Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:	NCT00267813

Purpose

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking and neutral cues in Positron Emission Tomography using FDG.

Condition	Intervention
Nicotine Dependence	Drug: Bupropion (Zyban)

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.

Resource links provided by NLM:

MedlinePlus related topics: Smoking

Drug Information available for: Bupropion hydrochloride Bupropion

U.S. FDA Resources

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:

Brain metabolic activity (FDG) in response to craving and neutral cues. [ Time Frame: 30-40 minutes ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Subjective ratings of craving [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]

Enrollment:	24
Study Start Date:	July 2004
Study Completion Date:	October 2007
Primary Completion Date:	October 2007 (Final data collection date for primary outcome measure)

Intervention Details:

1 tablet a day increasing to 2 tablets a day after a week

Detailed Description:

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.

Eligibility

Ages Eligible for Study:	20 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Cigarette smokers (over 1 pack a day)
Age 20-65, male-females

Exclusion Criteria:

Dependence on other substances
Psychiatric diagnosis
Neurological disorder
Obesity
Young persons
Pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00267813

Locations

Israel
Department of Nuclear Medicine
Tel Aviv, Israel, 64239

Sponsors and Collaborators

Tel-Aviv Sourasky Medical Center

Investigators

Principal Investigator:	Einat Even-Sapir, M.D, Ph.D	Tel-Aviv Sourasky Medical Center
Principal Investigator:	Aviv M Weinstein, Ph.D	Tel-Aviv Sourasky Medical Center
Study Director:	Hedva Lerman, M.D	Tel-Aviv Sourasky Medical Center

More Information

No publications provided by Tel-Aviv Sourasky Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Weinstein A, Greif J, Yemini Z, Lerman H, Weizman A, Even-Sapir E. Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion. J Psychopharmacol. 2010 Jun;24(6):829-38. Epub 2009 Jul 31.

Responsible Party:	Dr. Aviv M. Weinstein, Sourasky Medical Center Tel Aviv
ClinicalTrials.gov Identifier:	NCT00267813 History of Changes
Other Study ID Numbers:	TASMC-O5-EE-065-CTIL
Study First Received:	December 20, 2005
Last Updated:	May 6, 2008
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Tel-Aviv Sourasky Medical Center:

craving
nicotine
imaging
FDG

PET
smoking
Bupropion

Additional relevant MeSH terms:

Tobacco Use Disorder
Substance-Related Disorders
Mental Disorders
Bupropion
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents

Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 12, 2012